Navigation Links
Buprenorphine is better than methadone for opioid dependence in pregnant women, study shows
Date:12/9/2010

Using buprenorphine instead of methadone the current standard of care to treat opioid-dependent pregnant women may result in healthier babies, suggests new findings from an international team led by Johns Hopkins researchers and published in the Dec. 9 issue of the New England Journal of Medicine.

Babies born to mothers taking buprenorphine instead of methadone to counter heroin and/or prescription opioid addiction were likely to need less morphine to deal with drug withdrawal symptoms, spent half as much time in the hospital after delivery and recovered from neonatal abstinence syndrome in half as much time, the study found. Neonatal abstinence syndrome, caused when a fetus is exposed to heroin and/or prescription opioids in the womb, can cause hyperirritability and autonomic nervous system dysfunction, often requiring medication and extended hospital stays for babies born with it.

"In newborns, buprenorphine produces a milder withdrawal than methadone," says study leader Hendree Jones, Ph.D., a professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. "Our results support the use of buprenorphine as the treatment of choice for opioid dependence in pregnant women."

"The use of buprenorphine as an alternative treatment for opioid dependence during pregnancy had not been well studied," she adds, "making this research important in showing that buprenorphine is a better treatment option than methadone."

Jones cautions that buprenorphine is not for every opioid-dependent pregnant woman. Future research will focus on which drug is right for which type of patient, she says.

The study, an eight-site, double-blind, randomized, controlled trial titled The Maternal Opioid Treatment: Human Experimental Research (MOTHER) project, compared buprenorphine and methadone in the comprehensive care of 175 opioid-dependent women, ages 18 to 40, who were six to 30 weeks' pregnant.

Although not specifically FDA approved for such use, methadone, a synthetic opiate, is the accepted and recommended treatment for opioid dependence during pregnancy. Patients including pregnant women are prescribed methadone in an effort to keep them away from dangerous and illegal street drugs, including heroin, and the risky life issues associated with procuring and taking illegal drugs. Buprenorphine, a newer compound, is comparable to methadone, and both create similar side effects and outcomes for the mother.

Study participants received extensive prenatal and postnatal care and monitoring. Their care plans included psychological evaluations, blood work, sonograms, daily clinic visits, weekly questionnaires, a non-stress test, case management, and group and individual counseling. The mothers and newborns also were monitored for 28 days following delivery.


'/>"/>

Contact: Karen Tong
ktong4@jhmi.edu
410-550-0128
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. UTHealth study suggests private insurers control health care spending better than Medicare
2. Good grades in high school lead to better health, study finds
3. Cognitively-impaired human research subjects need better protection
4. Contaminated Butter Points to Need for Better Surveillance, Study Says
5. Littlest Kids in Big Day-Care Centers May Have Better Health Later On
6. Better imaging from bench to bedside
7. Active surveillance for low-risk prostate cancer may offer better quality-of-life
8. Better Outcomes Seen With Early Rheumatoid Arthritis Diagnosis
9. Screening tool may better identify heart disease in African-Americans
10. Work Teams Who Share Negative Emotions Better at Problem-Solving
11. Better Helmet Design Might Lower Soldiers Risk for Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: